BMJ, doi: 10.1136/bmj.38666.653600.55, (Published 8 December 2005)

PAPERS

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Christian M Jespersen 1*, Bodil Als-Nielsen 2, Morten Damgaard 1, Jørgen Fischer Hansen 1, Stig Hansen 3, Olav H Helø 4, Per Hildebrandt 5, Jørgen Hilden 6, Gorm B Jensen 3, Jens Kastrup 4, Hans Jørn Kolmos 7, Erik Kjøller 8, Inga Lind 9, Henrik Nielsen 2, Lars Petersen 5, Christian Gluud 10, Christian M Jespersen 10, the CLARICOR Trial Group

1 Bispebjerg Hospital, Copenhagen University Hospital, Department of Cardiology Y, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark
2 Amager Hospital, Copenhagen University Hospital, Department of Cardiology, DK-2300 Copenhagen
3 Hvidovre Hospital, Copenhagen University Hospital, Department of Cardiology, DK-2650 Hvidovre, Denmark
4 Rigshospitalet, Copenhagen University Hospital, The Heart Centre, Department of Medicine B, DK-2100 Copenhagen
5 Frederiksberg Hospital, Copenhagen University Hospital, Department of Cardiology E, DK-2000 Frederiksberg, Denmark
6 Department of Biostatistics, Institute of Public Health, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen
7 Department of Clinical Microbiology, Odense University Hospital, DK-5000 Odense, Denmark
8 Herlev Hospital, Copenhagen University Hospital, Department of Cardiology S, DK-2730 Herlev, Denmark
9 Statens Serum Institut, DK-2300 Copenhagen
10 The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Institute of Preventive Medicine and Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen

* Correspondence to: cmj01{at}bbh.hosp.dk.

Objective To determine if the macrolide clarithromycin affects mortality and cardiovascular morbidity in patients with stable coronary heart disease.

Design Centrally randomised multicentre trial. All parties at all stages were blinded. Analyses were by intention to treat.

Setting Five Copenhagen University cardiology departments and a coordinating centre.

Participants 13 702 patients aged 18 to 85 years who had a discharge diagnosis of myocardial infarction or angina pectoris in 1993-9 and alive in August 1999 were invited by letter; 4373 were randomised.

Interventions Two weeks' treatment with clarithromycin 500 mg/day or matching placebo.

Main outcome measures Primary outcome: composite of all cause mortality, myocardial infarction, or unstable angina pectoris during three years' follow-up. Secondary outcome: composite of cardiovascular mortality, myocardial infarction, or unstable angina pectoris. The outcomes were obtained from Danish registers and were blindly assessed by the event committee.

Results 2172 participants were randomised to clarithromycin and 2201 to placebo. We found no significant effects of clarithromycin on the primary outcome (hazard ratio 1.15, 95% confidence interval 0.99 to 1.34) or secondary outcome (1.17, 0.98 to 1.40). Mortality was significantly higher in the clarithromycin arm (1.27, 1.03 to 1.54; P=0.03) as a result of significantly higher cardiovascular mortality (1.45, 1.09 to 1.92; P=0.01).

Conclusions Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality. The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined.

Trial registration ClinicalTrials.gov NCT00121550.

(Accepted 17 October 2005)
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Listen to the data when results are not significant
Catherine E Hewitt, Natasha Mitchell, and David J Torgerson
BMJ 2008 336: 23-25. [Extract] [Full Text] [PDF]

Clarithromycin in stable coronary heart disease may increase mortality
BMJ 2006 332: 0. [Full Text]

The failure of antibiotics to prevent heart attacks
David Taylor-Robinson and Jens Boman
BMJ 2005 331: 361-362. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Jespersen, C. M., Kolmos, H. J., Frydendall, N., Hilden, J., Gluud, C., Hansen, J. F., on behalf of the CLARICOR Trial Group, (2009). Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. J Antimicrob Chemother 64: 411-415 [Abstract] [Full text]  
  • Kastrup, J., Johansen, J. S., Winkel, P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., Jespersen, C. M., Kjoller, E., Kolmos, H. J., Lind, I., Nielsen, H., Gluud, C., the CLARICOR Trial Group, (2009). High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30: 1066-1072 [Abstract] [Full text]  
  • Brok, J., Thorlund, K., Wetterslev, J., Gluud, C. (2009). Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 38: 287-298 [Abstract] [Full text]  
  • Volanen, I., Kallio, K., Saarinen, M., Jarvisalo, M. J., Vainionpaa, R., Ronnemaa, T., Viikari, J., Marniemi, J., Simell, O., Raitakari, O. T. (2008). Arterial Intima-Media Thickness in 13-Year-Old Adolescents and Previous Antichlamydial Antimicrobial Use: A Retrospective Follow-up Study. Pediatrics 122: e675-e681 [Abstract] [Full text]  
  • Hewitt, C. E, Mitchell, N., Torgerson, D. J (2008). Listen to the data when results are not significant. BMJ 336: 23-25 [Full text]  
  • Hilden, J. (2007). How should clinicians interpret results reflecting the effect of an intervention on composite end points?. Evid. Based Med. 12: 92-92 [Full text]  
  • Jensen, G. B., Hampton, J. (2007). Early termination of drug trials. BMJ 334: 326-326 [Full text]  
  • (2006). No Benefit of Clarithromycin in Stable Heart Disease. Journal Watch Cardiology 2006: 7-7 [Full text]  
  • (2006). Clarithromycin for CAD Patients -- No Benefit. JWatch General 2006: 8-8 [Full text]  
  • (2006). Macrolide Treatment Exacerbates Coronary Heart Disease. JWatch Infect. Diseases 2006: 3-3 [Full text]  

Rapid Responses:

Read all Rapid Responses

Atherosclerosis, antibiotics and infections: the uncertain road.
Gustavo E. Sevlever, et al.
bmj.com, 27 Dec 2005 [Full text]
Mortality of antibiotic therapy is not higher in stable coronary heart disease
Hisato Takagi, et al.
bmj.com, 7 Jan 2006 [Full text]
CLARICOR - what about the statins?
Stephen Head
bmj.com, 9 Jan 2006 [Full text]
Worrying study ... hang on, do the numbers add up?
Dr Matthew L Grove
bmj.com, 10 Jan 2006 [Full text]
The inability of randomised controlled trials to produce scientifically conclusive results
Jeffrey Mann
bmj.com, 11 Jan 2006 [Full text]
CLARICOR - not clear at all
Hoong Sern Lim
bmj.com, 13 Jan 2006 [Full text]
Does Claricor legitimately test the Chlamydia pneumoniae hypothesis ?
John DE Parratt
bmj.com, 17 Feb 2006 [Full text]
Bait and Switch
S. Stanley Young, et al.
bmj.com, 14 Mar 2006 [Full text]
The CLARICOR data are correct
CLARICOR Trial Group
bmj.com, 14 Mar 2006 [Full text]
The CLARICOR analyses were planned
The CLARICOR Trial Group
bmj.com, 9 May 2006 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ